Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients

Jae Hyoung Lim, Young-Hoon Ko, Sook Haeng Joe, Changsu Han, Moon-Soo Lee, Jaewon Yang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

This study examined the long-term effectiveness and tolerability of zonisamide for weight control in psychiatric outpatients using various psychotropic medications. We conducted a systematic chart review of 82 psychiatric outpatients with unwanted weight gain after the introduction of psychotropic drugs between January 2008 and September 2009 at Korea University Ansan Hospital. The primary outcome measure was the effect of zonisamide on body mass index (BMI). Additional outcome measures included safety and tolerability as assessed by the clinical global impression-severity of illness scale (CGI-S) and discontinuation rate. The mean final dose of zonisamide was 124.6±53.4mg/day and ranged from 50mg/day to 300mg/day. The mean BMI reduction was 0.8±1.7kg/m2 and ranged from -2.9kg/m2 to 4.7kg/m2 (p<0.001). We also observed a significant reduction in CGI-S scores from the baseline (3.8±0.9) to the endpoint (3.3±0.8; p<0.001). Twelve patients (14.6%) discontinued their zonisamide treatment due to its side effects. Patients treated with zonisamide showed significant weight loss. Furthermore, its treatment was generally safe and well tolerated with few negative effects on patients' overall psychiatric symptoms. Additional research is required to confirm these results and to investigate whether patients have rebound weight gains after discontinuing zonisamide.

Original languageEnglish
Pages (from-to)1918-1921
Number of pages4
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume35
Issue number8
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

zonisamide
Psychotropic Drugs
Psychiatry
Weight Loss
Outpatients
Weight Gain
Body Mass Index
Outcome Assessment (Health Care)
Korea

Keywords

  • Obesity
  • Psychotropic drugs
  • Weight
  • Zonisamide

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients. / Lim, Jae Hyoung; Ko, Young-Hoon; Joe, Sook Haeng; Han, Changsu; Lee, Moon-Soo; Yang, Jaewon.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 8, 01.12.2011, p. 1918-1921.

Research output: Contribution to journalArticle

@article{d31d54770736442597795f652a2d3efc,
title = "Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients",
abstract = "This study examined the long-term effectiveness and tolerability of zonisamide for weight control in psychiatric outpatients using various psychotropic medications. We conducted a systematic chart review of 82 psychiatric outpatients with unwanted weight gain after the introduction of psychotropic drugs between January 2008 and September 2009 at Korea University Ansan Hospital. The primary outcome measure was the effect of zonisamide on body mass index (BMI). Additional outcome measures included safety and tolerability as assessed by the clinical global impression-severity of illness scale (CGI-S) and discontinuation rate. The mean final dose of zonisamide was 124.6±53.4mg/day and ranged from 50mg/day to 300mg/day. The mean BMI reduction was 0.8±1.7kg/m2 and ranged from -2.9kg/m2 to 4.7kg/m2 (p<0.001). We also observed a significant reduction in CGI-S scores from the baseline (3.8±0.9) to the endpoint (3.3±0.8; p<0.001). Twelve patients (14.6{\%}) discontinued their zonisamide treatment due to its side effects. Patients treated with zonisamide showed significant weight loss. Furthermore, its treatment was generally safe and well tolerated with few negative effects on patients' overall psychiatric symptoms. Additional research is required to confirm these results and to investigate whether patients have rebound weight gains after discontinuing zonisamide.",
keywords = "Obesity, Psychotropic drugs, Weight, Zonisamide",
author = "Lim, {Jae Hyoung} and Young-Hoon Ko and Joe, {Sook Haeng} and Changsu Han and Moon-Soo Lee and Jaewon Yang",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.pnpbp.2011.07.007",
language = "English",
volume = "35",
pages = "1918--1921",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Zonisamide produces weight loss in psychotropic drug-treated psychiatric outpatients

AU - Lim, Jae Hyoung

AU - Ko, Young-Hoon

AU - Joe, Sook Haeng

AU - Han, Changsu

AU - Lee, Moon-Soo

AU - Yang, Jaewon

PY - 2011/12/1

Y1 - 2011/12/1

N2 - This study examined the long-term effectiveness and tolerability of zonisamide for weight control in psychiatric outpatients using various psychotropic medications. We conducted a systematic chart review of 82 psychiatric outpatients with unwanted weight gain after the introduction of psychotropic drugs between January 2008 and September 2009 at Korea University Ansan Hospital. The primary outcome measure was the effect of zonisamide on body mass index (BMI). Additional outcome measures included safety and tolerability as assessed by the clinical global impression-severity of illness scale (CGI-S) and discontinuation rate. The mean final dose of zonisamide was 124.6±53.4mg/day and ranged from 50mg/day to 300mg/day. The mean BMI reduction was 0.8±1.7kg/m2 and ranged from -2.9kg/m2 to 4.7kg/m2 (p<0.001). We also observed a significant reduction in CGI-S scores from the baseline (3.8±0.9) to the endpoint (3.3±0.8; p<0.001). Twelve patients (14.6%) discontinued their zonisamide treatment due to its side effects. Patients treated with zonisamide showed significant weight loss. Furthermore, its treatment was generally safe and well tolerated with few negative effects on patients' overall psychiatric symptoms. Additional research is required to confirm these results and to investigate whether patients have rebound weight gains after discontinuing zonisamide.

AB - This study examined the long-term effectiveness and tolerability of zonisamide for weight control in psychiatric outpatients using various psychotropic medications. We conducted a systematic chart review of 82 psychiatric outpatients with unwanted weight gain after the introduction of psychotropic drugs between January 2008 and September 2009 at Korea University Ansan Hospital. The primary outcome measure was the effect of zonisamide on body mass index (BMI). Additional outcome measures included safety and tolerability as assessed by the clinical global impression-severity of illness scale (CGI-S) and discontinuation rate. The mean final dose of zonisamide was 124.6±53.4mg/day and ranged from 50mg/day to 300mg/day. The mean BMI reduction was 0.8±1.7kg/m2 and ranged from -2.9kg/m2 to 4.7kg/m2 (p<0.001). We also observed a significant reduction in CGI-S scores from the baseline (3.8±0.9) to the endpoint (3.3±0.8; p<0.001). Twelve patients (14.6%) discontinued their zonisamide treatment due to its side effects. Patients treated with zonisamide showed significant weight loss. Furthermore, its treatment was generally safe and well tolerated with few negative effects on patients' overall psychiatric symptoms. Additional research is required to confirm these results and to investigate whether patients have rebound weight gains after discontinuing zonisamide.

KW - Obesity

KW - Psychotropic drugs

KW - Weight

KW - Zonisamide

UR - http://www.scopus.com/inward/record.url?scp=82455212951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82455212951&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2011.07.007

DO - 10.1016/j.pnpbp.2011.07.007

M3 - Article

C2 - 21803114

AN - SCOPUS:82455212951

VL - 35

SP - 1918

EP - 1921

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 8

ER -